Benzopyranyltetrazoles as antiasthma agents
AssigneeFisons Limited
InventorsJoachim Augstein, Hugh Cairns, Dennis Hunter, John King
Life of this patent
Estimating the term…
Abstract
There are described compounds of formula I, ##STR1## in which R.sub.5, R.sub.6, R.sub.7 and R.sub.8, which may be the same or different, are hydrogen, alkyl C2 to 6, alkoxy C2 to 8, hydroxy-alkoxy C3 to 8, and R.sub.5 may be hydroxy, provided that one or two of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are other than hydrogen, and pharmaceutically acceptable derivatives thereof. The compounds of formula I are indicated for use in the treatment of asthma, and pharmaceutical compositions containing them and processes for their preparation are also described.
Claims4
A pharmaceutical composition comprising:
- 5-(5-hydroxy-4-oxo-4H-1-benzopyran-2-yl)tetrazole or a pharmaceutically acceptable salt thereof as active ingredient, in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.
A method for treatment of allergic asthma which comprises administering 1 to 3500 mg. per day of 5-(5-hydroxy-4-oxo-4H-1-benzopyran-2-yl)tetrazole, to an asthmatic patient.
A pharmaceutical composition comprising:
- 5[6,8-di-t-butyl-4-oxo-4H-1-benzopyran-2-yl]tetrazole or a pharmaceutically acceptable salt thereof as active ingredient, in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.
A method for treatment of allergic asthma which comprises adminstering 1 to 3500 mg. per day of 5[6,8-di-t-butyl-4-oxo-4H-1-benzopyran-2-yl]tetrazole, to as asthmatic patient.
Dependencies are inferred from the claim text.